ImmunityBio Inc (NASDAQ:IBRX) stock is maintaining a confirmed Golden Cross, with the stock now trading roughly 170% above its 200-day moving average — a measurable signal of sustained long-term trend strength.

Chart created using Benzinga Pro

IBRX stock is currently trading near $8.04, while the 200-day moving average sits at approximately $2.95. The Golden Cross was established after the 50-day moving average rose above the 200-day moving average, and the widening gap between the two continues to reflect a strong upward trend.

IBRX Price Holding Well Above Key Trend Support Levels

IBRX stock is now trading above all major moving averages, confirming alignment across short-, medium-, and long-term trend indicators. The stock is about 24% above its 20-day moving average of $6.90 and roughly 91% above its 50-day moving average of $4.21.

Trading above these levels indicates sustained price strength over multiple timeframes. The 200-day moving average, in particular, serves as a widely followed indicator of long-term trend direction. Stocks holding significantly above this level are generally considered to be in established uptrends.

Momentum Indicators Confirm Trend Strength

ImmunityBio’s average daily trading volume has risen to approximately 1.7 million shares based on its 9-day volume average, reflecting increased market participation compared to earlier periods.

Momentum indicators also remain elevated. The Relative Strength Index (RSI) is currently near 67, indicating strong upward momentum while remaining below the overbought threshold of 70. This suggests sustained buying pressure without reaching extreme levels historically associated with short-term exhaustion.

Golden Cross Remains Intact

The 50-day moving average currently stands at $4.21, approximately 42% above the 200-day moving average. This confirms the persistence of the Golden Cross structure, which occurs when shorter-term price trends exceed long-term averages.

With price holding well above the 200-day level and momentum indicators remaining strong, ImmunityBio continues to maintain a technically confirmed long-term uptrend.

Image: Shutterstock